Welcome to InOncology.com

Discover how Boehringer Ingelheim is taking cancer on in order to transform patients' lives. Our long-term commitment to oncology is to pursue leading science to develop innovative cancer treatments across different tumor types.

LATEST CONGRESSES: OUR ACTIVITIES

Next event
ELCC 2021
ESMO Asia

Learn more about our symposium at the ESMO Asia Virtual Oncology Week 2021 (Nov 17-23)

Past event
IASLC WCLC 2020
CTOS 2021

Look into our latest data to be presented at the CTOS 2021 virtual annual meeting (Nov 10-13);

1 oral presentation

Past event
ASCO GI 2021
ESMO 2021

Explore data presented at the ESMO 2021 virtual congress (Sep 16–21);

11 poster presentations

Past event
ESMO Asia 2020 congress
IASLC WCLC 2021

Explore data presented at the IASLC WCLC 2021 virtual meeting (Sep 8-14);

2 poster presentations

Past event
asco-2021
ASCO 2021

Discover our activities at the virtual ASCO annual meeting 2021 (June 4–8);

8 poster presentations

Past event
AACR 2021
AACR 2021

Find out about our virtual activities at the AACR annual meeting 2021 (April 10-15);

11 posters and 1 oral presentation

RESOURCES

Physicians´ insights

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

 

**Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: November 2021